COVID-19 Treatment Studies for Ivermectin

The website c19ivm.org has compiled all peer-reviewed studies on ivermectin as a treatment for COVID-19. The results are profound:

Statistically significant improvements are seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. All remain significant after exclusions. 59 studies from 53 independent teams in 23 different countries show statistically significant improvements in isolation (41 primary outcome, 39 most serious outcome).
Meta analysis using the most serious outcome shows 62% [51‑70%] and 85% [77‑90%] improvement for early treatment and prophylaxis, with similar results after exclusion based sensitivity analysis, for primary outcomes, for peer-reviewed studies, and for RCTs.
Results are very robust — in worst case exclusion sensitivity analysis 61 of 96 studies must be excluded to avoid finding statistically significant efficacy.
No treatment, vaccine, or intervention is 100% effective and available. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, which may be significantly more effective. Only 22% of ivermectin studies show zero events with treatment. Pharmacokinetics show significant inter-individual variability [Guzzo]. Efficacy may vary depending on the manufacturer [Williams].
Over 20 countries adopted ivermectin for COVID-19. The evidence base is much larger and has much lower conflict of interest than typically used to approve drugs.
All data to reproduce this paper and sources are in the appendix. See [Bryant, Hariyanto, Kory, Lawrie, Nardelli] for other meta analyses showing efficacy.